BPG is committed to discovery and dissemination of knowledge
Articles in Press
1/16/2024 6:09:27 AM | Browse: 36 | Download: 0
Category |
Pharmacology & Pharmacy |
Manuscript Type |
Meta-Analysis |
Article Title |
Is tumor necrosis factor-α monoclonal therapy with proactive therapeutic drug monitoring optimized for inflammatory bowel disease? Network meta-analysis
|
Manuscript Source |
Unsolicited Manuscript |
All Author List |
Fang-Yuan Zheng, Kai-Si Yang, Wen-Cheng Min, Xin-Zhu Li, Yu Xing, Shuai Wang, Ying-Shi Zhang and Qing-Chun Zhao |
Funding Agency and Grant Number |
Funding Agency |
Grant Number |
National College Students Innovation and Entrepreneurship Training Program of Shenyang Pharmaceutical University |
No. 202210163003 |
|
Corresponding Author |
Ying-Shi Zhang, N/A, Lecturer, Teacher, Department of Clinical Pharmacy, Shenyang Pharmaceutical University, No. 103 Wenhua Road, Shenhe District, Shenyang 110016, Liaoning Province, China. zhangyingshi526@163.com |
Key Words |
Inflammatory bowel disease; Therapeutic drug monitoring; Adalimumab; Infliximab; Network meta-analysis |
Core Tip |
The efficacy and safety of anti-tumor necrosis factor-α monoclonal antibody therapy [adalimumab (ADA) and infliximab] with therapeutic drug monitoring (TDM), which has been proposed for inflammatory bowel disease (IBD) patients, are still controversial. In this study, we found that proactive TDM was more suitable for IBD patients treated with ADA and had obvious advantages over reactive TDM. |
Citation |
Zheng FY, Yang KS, Min WC, Li XZ, Xing Y, Wang S, Zhang YS, Zhao QC. Is tumor necrosis factor-α monoclonal therapy with proactive therapeutic drug monitoring optimized for inflammatory bowel disease? network meta-analysis. World J Gastrointest Surg 2024; 16(2): 571-584 |
 |
Received |
|
2023-10-29 14:04 |
 |
Peer-Review Started |
|
2023-10-29 14:06 |
 |
To Make the First Decision |
|
|
 |
Return for Revision |
|
2023-12-06 06:23 |
 |
Revised |
|
2023-12-14 13:17 |
 |
Second Decision |
|
2024-01-16 02:46 |
 |
Accepted by Journal Editor-in-Chief |
|
|
 |
Accepted by Executive Editor-in-Chief |
|
2024-01-16 06:09 |
 |
Articles in Press |
|
2024-01-16 06:09 |
 |
Publication Fee Transferred |
|
|
 |
Edit the Manuscript by Language Editor |
|
2024-01-14 14:28 |
 |
Typeset the Manuscript |
|
2024-02-07 07:57 |
ISSN |
1948-9366 (online) |
Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
Copyright |
© The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved. |
Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
Website |
http://www.wjgnet.com |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345